Research shows why 1960s RSV shot sickened children

By Anne Harding

NEW YORK (Reuters Health) - Researchers from Johns Hopkins have solved the decades-old mystery of why a vaccine developed to prevent a common childhood viral infection wound up making kids sick.

The findings provide important clues to how to develop a safe, effective vaccine against respiratory syncytial virus (RSV), the main cause of wintertime hospital stays among babies and young children worldwide, Dr. Fernando P. Polack, the lead researcher on the study, told Reuters Health.

“A big concern for the scientists involved in RSV vaccine development is to make sure we do not repeat the same situation again,” said Polack, who is also affiliated with the INFANT Foundation in Buenos Aires.

In the late 1960s, children in Washington, DC received an RSV vaccine in which the virus was inactivated with formalin. Eighty percent of the children given the shot were hospitalized with severe respiratory disease, and two died. Many scientists had thought the formalin was responsible for the vaccine’s problems, but the chemical has been used safely in other vaccines.

For eight years, Polack and his team have been investigating why the vaccine caused the illness, known as enhanced respiratory disease, or ERD. They started by examining tissue from the lungs of the two patients who died, and comparing the effects of the vaccine to RSV itself in mice.

The problem, they report this month in the journal Nature Medicine, was that the children’s antibodies were not binding strongly enough to the inactivated virus to produce a protective immune response. Instead, the antibodies were dragging the dead virus with them, triggering a massive attack by other arms of the immune system.

The inactivated vaccine was only weakly stimulating molecules on the surfaces of cells that are responsible for recognizing infectious invaders and triggering an appropriate immune response, the researchers say. So an effective vaccine would need to do a better job of stimulating these molecules, known as Toll-like receptors, Polack explained.

Most likely, the researcher said, making an effective and safe RSV vaccine will require developing an attenuated form of the virus, meaning a strain that is too weak to cause infection but active enough to stimulate the Toll-like receptors adequately.

Such a vaccine is sorely needed, Polack said. Half of children develop RSV infections before their first birthdays, the researcher noted, while by age 2, 95 percent have been infected. About half the time, the infection only produces a cold, while in the other half of cases the infection enters the lungs and causes infection of the small airways, or bronchiolitis. A child will usually get better on his or her own, but in about one in 100 cases, the child will need to be hospitalized and be given oxygen. RSV kills a half million people worldwide every year.

SOURCE: Nature Medicine, online December 14, 2008.

Source

--------------------------------------------------------------------------------------------
Related Posts:


By Andrew Quinn WASHINGTON (Reuters) - A global AIDS vaccine conference this week will seek fresh strategies against the HIV virus, with experts weighing the value of basic laboratory research against large-scale human clinical trials after a string of disappointments. Approaches focusing on “neutralizing antibodies” that would allow the human immune system to block infection completely, are

Full Post: AIDS vaccine focus shifts after disappointments
--------------------------------------------------------------------------------------------

By David Douglas NEW YORK (Reuters Health) - Human metapneumovirus, which was first identified in 2001 in children, is among the respiratory viruses that affect adults of all ages, New York-based researchers have found. The study, Dr. Edward E. Walsh told Reuters Health, “demonstrates that repeat infections with childhood viruses are common in all adults, and along

Full Post: Metapneumovirus infections seen widespread in adults
--------------------------------------------------------------------------------------------

NEW YORK (Reuters Health) - The risk of hearing loss due to congenital cytomegalovirus (CMV) infection is greater when the mother-to-be is infected with the virus in the first three months of pregnancy rather than later in the pregnancy, researchers have found. More than half of the population is infected with CMV, a type of herpesvirus.

Full Post: Mom’s infection raises risk of infant hearing loss
--------------------------------------------------------------------------------------------

By Laura MacInnis GENEVA (Reuters) - The body’s initial response to contracting HIV could provide the answers scientists need to develop a vaccine for the AIDS-causing virus, a Nobel-winning expert said on Monday. The AIDS epidemic has killed about 25 million people, and about 33 million worldwide are now infected with HIV. Cocktails of drugs can control

Full Post: First days after HIV infection may hold vaccine key
--------------------------------------------------------------------------------------------

By Megan Rauscher NEW YORK (Reuters Health) - Even in an influenza season where there is not an optimal match between circulating strains of influenza and the strains contained in the influenza vaccine, the vaccine is likely to significantly protect young children, ages 6 to 59 months, against influenza, new research indicates. Influenza vaccine effectiveness has not

Full Post: Influenza vaccine effective in young children

Site Navigation

Most Read

Search